ReviewCirculation research2021
New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease.
Review in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 1 synthesis or guideline pooled it, 201 citations in OpenAlex.
- Paclitaxel-coated balloon versus paclitaxel-eluting stent for femoropopliteal arterial disease: A meta-analysis.Medicine · 2025Pooled it
- FPR1-Driven Neutrophil-Endothelial Cell Axis Promotes Angiogenesis in PAOD.Circulation research · 2026Article
- Liposome-iRGD loaded with astragaloside IV alleviates the functional damage of endothelial progenitor cells via the Hippo-YAP/TAZ signaling pathway.In vitro cellular & developmental biology. Animal · 2026Article
- Endothelial progenitor cells-derived exosomes reduce ferroptosis and promote neovascularization after intracranial atherosclerosis in association with the NCOA4/FTH1 cascade modulation.Drug delivery and translational research · 2026Article
- GNPs-pIL-4 reprograms macrophage polarization and activates the OSM/GSNOR/ENG axis to improve angiogenesis in ischemic limbs.Science advances · 2026Article
- Article
- Biomimetic injectable engineered hierarchical porous microspheres for enhanced synergistic cell therapy of critical limb ischemia.Bioactive materials · 2026Article
- Surgical Rodent Models for the Study of Peripheral Arterial Disease.Biomedicines · 2026Review
- Development and Internal Validation of an Explainable Machine Learning Model for Predicting Buttock Claudication After EVAR: A Dual-Center Cohort Study.Bioengineering (Basel, Switzerland) · 2026Article
- Indoleacrylic acid mitigates vascular rarefaction and enhances ischemia-induced neovascularization in aging via APLNR signaling.Acta pharmacologica Sinica · 2026Article
- HK2 promotes angiogenesis through H3K18 lactylation in peripheral arterial disease.Communications biology · 2026Article
- ATP-citrate lyase is a critical regulator of physiological and pathological angiogenesis.Angiogenesis · 2026Article
- Age and Sex Impact the Role of Thrombospondin-2 and Thrombospondin-5 in Response to Hindlimb Ischemia.FASEB bioAdvances · 2026Article
- Human Atlas of Tooth Decay Progression: Identification of Cellular Mechanisms Driving the Switch from Dental Pulp Repair Toward Irreversible Pulpitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precise Delivery of Nitric Oxide Controlled by Bioorthogonal Endocellulase Ameliorates Hindlimb Ischemia.Bioengineering (Basel, Switzerland) · 2026Article
- Investigating the Role of Glycolysis in Xuefu Zhuyu Capsule-Promoted Angiogenesis in Endothelial Cells: A Study Based on Network Pharmacology, Molecular Docking, and In Vitro Validation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Profiling of main regulators of angiogenesis and inflammation in human PBMC and plasma revealed associations with lower extremity artery disease.Scientific reports · 2025Article
- Burden of lower-limb peripheral arterial disease in China and its comparison with global estimates, 1990-2021: analysis of global burden of disease (GBD) data by sex and age group.BMC cardiovascular disorders · 2025Article
- Extracellular vesicle R-Ras is a potential biomarker for human peripheral artery disease.iScience · 2025Article
- Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The prevalence of peripheral arterial disease (PAD) in the United States exceeds 10 million people, and PAD is a significant cause of morbidity and mortality across the globe. PAD is typically caused by atherosclerotic obstructions in the large arteries to the leg(s). The most common clinical consequences of PAD include pain on walking (claudication), impaired functional capacity, pain at rest, and loss of tissue integrity in the distal limbs that may lead to lower extremity amputation. Patients with PAD also have higher than expected rates of myocardial infarction, stroke, and cardiovascular death. Despite advances in surgical and endovascular procedures, revascularization procedures may be suboptimal in relieving symptoms, and some patients with PAD cannot be treated because of comorbid conditions. In some cases, relieving obstructive disease in the large conduit arteries does not assure complete limb salvage because of severe microvascular disease. Despite several decades of investigational efforts, medical therapies to improve perfusion to the distal limb are of limited benefit. Whereas recent studies of anticoagulant (eg, rivaroxaban) and intensive lipid lowering (such as PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) have reduced major cardiovascular and limb events in PAD populations, chronic ischemia of the limb remains largely resistant to medical therapy. Experimental approaches to improve limb outcomes have included the administration of angiogenic cytokines (either as recombinant protein or as gene therapy) as well as cell therapy. Although early angiogenesis and cell therapy studies were promising, these studies lacked sufficient control groups and larger randomized clinical trials have yet to achieve significant benefit. This review will focus on what has been learned to advance medical revascularization for PAD and how that information might lead to novel approaches for therapeutic angiogenesis and arteriogenesis for PAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.